Table of Contents
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition - Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Respiratory Pipeline
4 Market Outlook
4.1 Product Pipeline
4.2 Market Segmentation
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising prevalence of cystic fibrosis diseases
5.1.1.2 Advancements in screening and treatments technology
5.1.1.3 High prevalence of tobacco smoking
5.1.2 Restraints
5.1.2.1 Complex drug development process
5.1.2.2 Expensive treatment options for cystic fibrosis
5.1.3 Opportunities
5.1.3.1 Initiatives from government and other organization
5.1.3.2 Promising pipeline for the treatment of cystic fibrosis
5.1.3.3 Market expansion opportunities in emerging nations
5.1.4 DRO - Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.1 Overview
6.2 CFTR Modulators
6.3 Mucolytics
6.4 Bronchodialators
6.5 Pancreatic Enzyme Supplements
6.6 Others
7 Route of Administration: Market Size and Analysis
7.1 Overview
7.2 Oral 7.3 Inhalation
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 Overview 37
8.3 Europe
8.3.1 Overview
8.4 Asia Pacific
8.4.1 Overview
8.5 Rest of the World
8.5.1 Overview
9 Competitive Landscape 48
10 Vendors Profile 50
10.1 AbbVie 50
10.2 F. Hoffmann-La Roche 52
10.3 Gilead Sciences, Inc. 54
10.4 Vertex Pharmaceuticals 57
10.5 Novartis 60
11 Companies to Watch for 64
11.1 Advanced Inhalation Therapies (AIT) Ltd. 64
11.2 Alcresta Therapeutics, Inc. 65
11.3 Allergan Plc 66
11.4 AstraZeneca 67
11.5 Merck & Co. Inc 68
11.6 PharmaSwiss 69
Annexure 71
Acronyms 71